TLR4 and Parkinson disease: Further mechanistic studies demonstrate that FMT administration reverses the gut microbiota dysbiosis and protects the PD mouse model, in which suppression of the inflammation mediated by the LPS-TLR4 signaling pathway both in the gut and the brain possibly plays a significant role.